Novo Nordisk (NVO), the Danish pharmaceutical leader, has reclaimed its dominance in the GLP-1 market, driven by strategic agility and innovative breakthroughs.
Known for its blockbuster drugs Ozempic and Wegovy, Novo faced fierce competition from Eli Lilly’s (LLY) Mounjaro and Zepbound, which captured market share with superior weight-loss results. Compounding pharmacies further challenged Novo by offering cheaper alternatives during GLP-1 shortages.
Yet, through a series of calculated moves, Novo has staged a remarkable comeback, with its stock soaring 27% from recent lows.
This post originally appeared at Money Morning.